MHRAsafety guidance72% confidence
Risk of severe harm from use of incorrect giving (administration) set for blood transfusion (DSI/2026/003)
Source: MHRA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (liver cancer) as Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial.
Regulatory Analysis
There is a potential for serious harm to patients if an intravenous (IV) infusion giving set is used instead of a blood transfusion giving set to deliver a transfusion of blood or blood components.
Supporting Context
- Therapeutic area
- Oncology · Liver Cancer
- Sub-indication
- Liver Cancer
Related signal: Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial